A closer look at “STAT+: Gossamer lung disease drug fails late-stage study, but company will still seek FDA ”, exactly as the source publishes it. Gossamer Bio's drug for pulmonary arterial hypertension failed to achieve the primary endpoint of a Phase 3 clinical trial. Nova Global News curates publicly available headlines and summaries with source attribution. Third-party article rights, trademarks, images, and publisher names belong to their respective owners;
read the original article at the source for full context. Part of the Nova Ecosystem — the platform where AI apps, news, and tools are built and deployed. [ LIVE 🧠 Nova Ecosystem PLATFORM Our Platform Nova AI MetaBrain 84 AI Assistants — Videos, images, code & more. For the complete material, the listing points back to the source inside the network.